1. Patterns and predictors of statin therapy after ischemic stroke and TIA: insights from the LIPYDS multicenter study.
- Author
-
Cascio Rizzo A, Schwarz G, Paolucci M, Cavallini A, Mazzacane F, Candelaresi P, De Mase A, Marcheselli S, Straffi L, Poretto V, Giometto B, Diomedi M, Bagnato MR, Zedde M, Grisendi I, Petruzzellis M, Galotto D, Morotti A, Padovani A, Bonaffini N, Cupini LM, Caso V, Bossi F, Fanciulli C, Viola MM, Persico A, Spina E, Falcou A, Pantoni L, Mele F, Silvestrini M, Viticchi G, Pilato F, Cappellari M, Anticoli S, La Spina P, Sessa M, Toni D, Zini A, and Agostoni EC
- Abstract
Background: Patients with ischemic stroke (IS) or TIA face an elevated cardiovascular risk, warranting intensive lipid-lowering therapy. Despite recommendations, adherence to guidelines is suboptimal, leading to frequent undertreatment. This study aims to evaluate the statin use after IS and TIA., Methods: LIPYDS is a multicenter, observational, retrospective study including ≥ 18-year-old patients discharged after IS/TIA from 19 Italian centers in 2021. Multivariable logistic regression analysis was used to determine (1) the association between statin prescription (Any-statin versus No-statin), type (High-Intensity-statin versus Other-statin [Moderate/Low-Intensity]) with stroke etiology (TOAST), (2) clinical variables independently associated with statin prescription in the entire cohort and within TOAST categories., Results: We included 3,740 patients (median age 75 [IQR 64-82]; median LDL-C 104 [IQR 79-131]). At discharge, 1,971 (52.7%) received a High-intensity-statin, 800 (21.4%) Other-statin, 969 (25.9%) No-statin therapy. Among patients not on statin therapy before the event (N = 2686 [71.8%]), 50.1% initiated High-intensity-statin (78.2% of those with Large-Artery-Atherosclerosis, 60.8% Small-Vessel-Disease, 34.7% Cardioembolic, 47.4% Undetermined etiology); in 33% the decision to abstain from initiating statin therapy persisted. Large-Artery-Atherosclerosis showed the strongest association with Any-statin (aOR 3.07 [95%CI 2.39-3.95], p < 0.001) and High-intensity-statin (aOR 4.51 [95%CI 3.39-6.00], p < 0.001), while Cardioembolic stroke showed an inverse association (respectively, aOR 0.36 [95%CI 0.31-0.43], p < 0.001 and aOR 0.52 [95%CI 0.44-0.62], p < 0.001). Stepwise regression highlighted LDL-C and previous statin therapy as consistent predictors of statin at discharge. Older patients and women were less likely to be on a high-intensity formulation., Conclusion: Statins, especially at high-intensity, are under-prescribed after IS and TIA, with older patients, women and those with non-atherosclerotic strokes being the most affected., Competing Interests: Declarations. Conflict of interest: Andrea Zini received funding for speaker honoraria and consulting fees from Daiichi-Sankyo, Bayer, CSL Behring, Angels Initiative, Alexion-AstraZeneca, for scientific advisory board from Alexion-AstraZeneca and Bayer. Manuel Cappellari received consultancy or advisory board fees or speaker’s honoraria from Pfizer/Bristol-Meyer-Squibb, and Daiichi-Sankyo. All other co-authors have no relevant competing interests related to this study. Ethical statement: This study was approved by the local Ethical Committee (Comitato Etico Milano Area 3, n. 290-20042022)., (© 2024. Fondazione Società Italiana di Neurologia.)
- Published
- 2025
- Full Text
- View/download PDF